Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
AstraZeneca’s Oral SERD, MSD RSV Antibody Up for Japan Panel Review on May 25
Quick Look: Five NMEs are up for MHLW panel review on May 25: AstraZeneca’s camizestrant, MSD’s clesrovimab, Sobi’s anakinra, Novartis’ remibrutinib, and Sun Pharma’s isotretinoin. The session will also cover label expansions for Tibsovo, Sarclisa, Retevmo, Minjuvi, Tevimbra, Imfinzi, and…
To read the full story
Related Article
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
- J&J Seeks Nod for Talvey-Tecvayli Bispecific Combo in Multiple Myeloma
November 4, 2025
- Sanofi Files for Subcutaneous Formulation of Sarclisa in Japan
August 29, 2025
- MSD Seeks Japan Nod for RSV Antibody Clesrovimab
July 15, 2025
- Servier Files Tibsovo for Biliary Tract Cancer in Japan
July 1, 2025
REGULATORY
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
- CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
- MHLW Urges Stakeholders to Define Essential LLP Information
July 14, 2026
- Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
- Immunization Act Revision Faces Uncertain Fate as Diet Clock Ticks Down
July 13, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…